You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 27 No. 6, December 1972 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (30)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Catecholamines and Indoleamines in Patients With Duchenne Muscular Dystrophy

Jerry R. Mendell, MD; Dennis L. Murphy, MD; W. King Engel, MD; Thomas N. Chase, MD; Edna Gordon, MS

Arch Neurol. 1972;27(6):518-520.


Abstract

Several studies have raised the question of abnormal biogenic amine metabolism in Duchenne muscular dystrophy (DMD). A small group of DMD patients and controls were screened for abnormalities in systemic biogenic amine metabolism in a carefully controlled clinical environment The mean 24-hour urinary excretion levels of norepinephrine, epinephrine, and 5-hydroxyindoleacetic acid (5-HIAA) were identical in the group of DMD patients compared to their normal sibling controls. In the cerebrospinal fluid (CSF), 5-HIAA and homovanillic acid (HVA) levels were similar in DMD patients and controls, and no 5-hydroxytryptamine (5-HT) was detected in the CSF of either group. This study suggests that the characteristic lesions of DMD do not result from a simple excess of circulating amines.



Author Affiliations

Bethesda, Md

From the Medical Neurology Branch, National Institute of Neurological Diseases and Stroke, and the Laboratory of Clinical Science, National Institute of Mental Health, National Institutes of Health, Bethesda, Md.


Footnotes

Accepted for publication June 28, 1972.

Reprint requests to Medical Neurology Branch, National Institutes of Health, Bethesda, Md 20014 (Dr. Mendell).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Muscular Dystrophies and Related Disorders: I. The Muscular Dystrophies
Furukawa and Peter
JAMA 1978;239:1537-1542.
ABSTRACT  

Biochemical Abnormalities of Erythrocyte Membranes in Duchenne Dystrophy: Adenosine Triphosphatase and Adenyl Cyclase
Mawatari et al.
Arch Neurol 1976;33:489-493.
ABSTRACT  

Pathogenesis of Muscular Dystrophies
Rowland
Arch Neurol 1976;33:315-321.
ABSTRACT  

Serotonin-Induced Muscle Weakness
Patten et al.
Arch Neurol 1974;31:347-349.
ABSTRACT  

Serotonin and Platelet Function in Duchenne Muscular Dystrophy
Murphy et al.
Arch Neurol 1973;28:239-242.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1972 American Medical Association. All Rights Reserved.